Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
|Articles|June 17, 2021
- Pharmaceutical Commerce - June 2021
- Volume 16
- Issue 2
2021 Pharma Traceability Vendor Directory
Advertisement
Articles in this issue
over 5 years ago
Pharmaceutical Commerce - June 2021 Issue (PDF)over 5 years ago
Building a better supply chainover 5 years ago
Staring down supply chain disruptionover 5 years ago
Automation for the peopleover 5 years ago
RFID on the rise again in pharmaover 5 years ago
People, production, and prioritiesover 5 years ago
The march to DSCSA interoperabilityover 5 years ago
Plan of attack for small company supplier negotiationsover 5 years ago
Building a future pandemic blueprintover 5 years ago
Algorithms and accountabilityAdvertisement
Related to this article
Octapharma USA's Kerem Tokel, a LogiPharma USA 2026 freight security panelist, discusses theft hotspots, the export of stolen pharmaceutical loads and how to tighten chain of custody.
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
At LogiPharma USA 2026, Mark Talens explains how end-to-end visibility lets pharma see its value chain across functions, and where supply chain monitoring is headed next.
BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase starts with the basics.
At LogiPharma USA 2026, Freehand's Nitin Jayakrishnan explains why AI and the people supply chain will shape pharma supply strategy.
Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
Cencora’s Matt Sample and Gregg Gorniak explain why AI should recommend, not decide, and why pharma needs an agent strategy before chasing use cases.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How an FTZ Builds More Flexibility Into Pharmaceutical Inventory Strategy
2
Q&A: Kerem Tokel on Pharma Cargo Theft Hotspots and the Shift to Outbound Diversion
3
What DOL’s Final PBM Rule Means for Rebates and Formularies
4
Why the Best Drug Launches Are Built to Adapt
5